And here is the full release from the PrEPVacc team. It is disappointing as the last HIV vaccine efficacy trial in the field — but important to note that the oral PrEP arms of the trial (looking to compare F/TDF to F/TAF among cisgender women for the first time is continuing). And the HIV vaccine field had already begun to pivot its focus on smaller “discovery medicine” trials that are looking at a number of new vaccine approaches — still a long way from efficacy trials and a potential licensed product, but very important iterative research. More at https://avac.org/resource/report/experimental-medicine-vaccine-trials-emvts-opportunities-and-challenges/.
